GATT seems to have done a lot of good to Glaxo. Consequent to changes in us patent laws, the company's patent for its renowned anti-ulcer drug Zantac has won an extension up to July 25, 1997. That gives an 18-month reprieve -- and nearly $5 billion in additional sales -- to the drug.
Pharmaceutical giants like Switzerland's Ciba were preparing to launch rival products in the us when Zantac's patent expired on December 5, 1994. To comply with gatt's regulations, the us announced that it would now honour patents for 20 years, which were previously valid for 17 years from the date of filing the patent application.
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.